Chemotherapy-Induced Nausea and Vomiting

Complete response does not capture subjective nausea severity, motivating nausea non-occurrence as a primary endpoint. The trial defines complete response as no vomiting and no rescue therapy during the first 120 hours after chemotherapy starts. Even guideline-recommended prevention does not fully control CINV in many patients receiving moderately or highly emetogenic chemotherapy. Non-occurrence of nausea has recently been used as a primary endpoint in CINV clinical trials. Nausea remains difficult to control even with modern antiemetic regimens. One cited study found that only 37% of patients had no nausea within 120 hours after chemotherapy. CINV is considered one of the most troublesome adverse effects of antineoplastic therapy. Chemotherapy-induced nausea and vomiting is a common toxicity of cancer treatment that can affect most patients without prophylaxis. CINV negatively affects patients' quality of life and can also affect families. Untreated CINV can reduce treatment adherence and directly affect prognosis. Poor control of CINV can reduce quality of life and treatment adherence and may affect survival outcomes.